New Approaches Are Shifting the Landscape in Immune Thrombocytopenia
June 24, 2019
During a recent OncLive Peer Exchange discussion, a trio of immune thrombocytopenia specialists review clinical trial data that led to approval of the second-line agents, talk about efforts to refine first-line treatment, and discuss how they approach therapy selection for
refractory patients. Finally, they highlight emerging therapies for ITP and the need to expand the pipeline.